{"denoms":[{"counts":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"13"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"528"},{"groupId":"BG010","value":"590"}],"units":"Participants"}],"groups":[{"description":"Participants received pralsetinib 30 milligrams (mg) orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG000","title":"Phase I: Pralsetinib 30 mg"},{"description":"Participants received pralsetinib 60 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG001","title":"Phase I: Pralsetinib 60 mg"},{"description":"Participants received pralsetinib 100 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG002","title":"Phase I: Pralsetinib 100 mg"},{"description":"Participants received pralsetinib 200 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG003","title":"Phase I: Pralsetinib 200 mg"},{"description":"Participants received pralsetinib 300 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG004","title":"Phase I: Pralsetinib 300 mg"},{"description":"Participants received pralsetinib 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG005","title":"Phase I: Pralsetinib 400 mg"},{"description":"Participants received pralsetinib 600 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG006","title":"Phase I: Pralsetinib 600 mg"},{"description":"Participants received pralsetinib 100 mg, orally, twice a day (BID) until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG007","title":"Phase I: Pralsetinib 100/100 mg"},{"description":"Participants received pralsetinib 200 mg in the morning and then 100 mg in the evening orally until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG008","title":"Phase I: Pralsetinib 200/100 mg"},{"description":"Participants with advanced NSCLC, advanced non-resectable TC and other advanced non-resectable solid tumors with various rearranged during transfection (RET)-alterations were enrolled in this arm to receive pralsetinib, 400 mg, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"BG009","title":"Phase II: Pralsetinib 400 mg"},{"description":"Total of all reporting groups","id":"BG010","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.2","value":"54.5"},{"groupId":"BG001","spread":"18.0","value":"49.5"},{"groupId":"BG002","spread":"13.2","value":"51.2"},{"groupId":"BG003","spread":"13.6","value":"53.8"},{"groupId":"BG004","spread":"11.0","value":"60.6"},{"groupId":"BG005","spread":"17.8","value":"49.2"},{"groupId":"BG006","spread":"9.1","value":"59.5"},{"groupId":"BG007","spread":"11.09","value":"63.0"},{"groupId":"BG008","spread":"18.25","value":"61.8"},{"groupId":"BG009","spread":"12.6","value":"57.7"},{"groupId":"BG010","spread":"12.8","value":"57.5"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"3"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"257"},{"groupId":"BG010","value":"283"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"7"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"4"},{"groupId":"BG008","value":"2"},{"groupId":"BG009","value":"271"},{"groupId":"BG010","value":"307"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"3"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"19"},{"groupId":"BG010","value":"28"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"465"},{"groupId":"BG010","value":"516"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"44"},{"groupId":"BG010","value":"46"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"203"},{"groupId":"BG010","value":"209"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"},{"groupId":"BG010","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"4"},{"groupId":"BG010","value":"6"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"11"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"3"},{"groupId":"BG008","value":"4"},{"groupId":"BG009","value":"284"},{"groupId":"BG010","value":"331"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"3"},{"groupId":"BG010","value":"3"}]}],"title":"Other"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"32"},{"groupId":"BG010","value":"39"}]}],"title":"Unknown or Not Reported"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Safety population included all participants who had received at least 1 dose of the study drug regardless of the starting dose levels."}